|
1
|
Sauvaget C, Nishino Y, Konno R, Tase T,
Morimoto T and Hisamichi S: Challenges in breast and cervical
cancer control in Japan. Lancet Oncol. 17:e305–e312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schoemaker MJ, Jones ME, Wright LB,
Griffin J, McFadden E, Ashworth A and Swerdlow AJ: Psychological
stress, adverse life events and breast cancer incidence: A cohort
investigation in 106,000 women in the United Kingdom. Breast Cancer
Res. 18:722016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yan X, Han R, Zhou J, Yu H, Yang J and Wu
M: Incidence, mortality and survival of female breast cancer during
2003–2011 in Jiangsu province, China. Chin J Cancer Res.
28:321–329. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Golubnitschaja O, Debald M, Yeghiazaryan
K, Kuhn W, Pešta M, Costigliola V and Grech G: Breast cancer
epidemic in the early twenty-first century: Evaluation of risk
factors, cumulative questionnaires and recommendations for
preventive measures. Tumour Biol. 37:12941–12957. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee JY and Kong G: Roles and epigenetic
regulation of epithelial-mesenchymal transition and its
transcription factors in cancer initiation and progression. Cell
Mol Life Sci. 73:4643–4660. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kasai H: What causes human cancer?
Approaches from the chemistry of DNA damage. Genes Environ.
38:192016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song Y, Wu F and Wu J: Targeting histone
methylation for cancer therapy: ENzymes, inhibitors, biological
activity and perspectives. J Hematol Oncol. 9:492016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shui IM, Wong CJ, Zhao S, Kolb S, Ebot EM,
Geybels MS, Rubicz R, Wright JL, Lin DW, Klotzle B, et al: Prostate
tumor DNA methylation is associated with cigarette smoking and
adverse prostate cancer outcomes. Cancer. 122:2168–2177. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duarte-Pereira S, Paiva F, Costa VL,
Ramalho-Carvalho J, Savva-Bordalo J, Rodrigues A, Ribeiro FR, Silva
VM, Oliveira J, Henrique R and Jerónimo C: Prognostic value of
opioid binding protein/cell adhesion molecule-like promoter
methylation in bladder carcinoma. Eur J Cancer. 47:1106–1114. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou F, Tao G, Chen X, Xie W, Liu M and
Cao X: Methylation of OPCML promoter in ovarian cancer tissues
predicts poor patient survival. Clin Chem Lab Med. 52:735–742.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou F, Ma M, Tao G, Chen X, Xie W, Wang Y
and Cao X: Detection of circulating methylated opioid binding
protein/cell adhesion molecule-like gene as a biomarker for ovarian
carcinoma. Clin Lab. 60:759–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J,
Zhang Q, Jin J, Liu D, Rhim JS, Rha SY, et al: OPCML is a broad
tumor suppressor for multiple carcinomas and lymphomas with
frequently epigenetic inactivation. PLoS One. 3:e29902008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu CW, Lin HW, Yang DJ, Chen SY, Tseng
JK, Chang TJ and Chang YY: Luteolin inhibits viral-induced
inflammatory response in RAW264.7 cells via suppression of STAT1/3
dependent NF-κB and activation of HO-1. Free Radic Biol Med.
95:180–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Lee IM, Zhang SM, Blumberg JB,
Buring JE and Sesso HD: Dietary intake of selected flavonols,
flavones, and flavonoid-rich foods and risk of cancer in
middle-aged and older women. Am J Clin Nutr. 89:905–912. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gates MA, Tworoger SS, Hecht JL, De Vivo
I, Rosner B and Hankinson SE: A prospective study of dietary
flavonoid intake and incidence of epithelial ovarian cancer. Int J
Cancer. 121:2225–2232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Landis-Piwowar KR, Milacic V and Dou QP:
Relationship between the methylation status of dietary flavonoids
and their growth-inhibitory and apoptosis-inducing activities in
human cancer cells. J Cell Biochem. 105:514–523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Z, Liu S, Xie Z, Blum W, Perrotti D,
Paschka P, Klisovic R, Byrd J, Chan KK and Marcucci G:
Characterization of in vitro and in vivo hypomethylating effects of
decitabine in acute myeloid leukemia by a rapid, specific and
sensitive LC-MS/MS method. Nucleic Acids Res. 35:e312007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sellar GC, Watt KP, Rabiasz GJ, Stronach
EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B,
Scott D, et al: OPCML at 11q25 is epigenetically inactivated and
has tumor-suppressor function in epithelial ovarian cancer. Nat
Genet. 34:337–343. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li C, Tang L, Zhao L, Li L, Xiao Q, Luo X,
Peng W, Ren G, Tao Q and Xiang T: OPCML is frequently methylated in
human colorectal cancer and its restored expression reverses EMT
via downregulation of smad signaling. Am J Cancer Res. 5:1635–1648.
2015.PubMed/NCBI
|
|
20
|
Blum W and Marcucci G: Targeting
epigenetic changes in acute myeloid leukemia. Clin Adv Hematol
Oncol. 3:855–865, 882. 2005.PubMed/NCBI
|
|
21
|
Guerrero L, Castillo J, Quiñones M,
Garcia-Vallvé S, Arola L, Pujadas G and Muguerza B: Inhibition of
angiotensin-converting enzyme activity by flavonoids:
Structure-activity relationship studies. PLoS One. 7:e494932012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu YC, Leung SW, Yeung DK, Hu LH, Chen GH,
Che CM and Man RY: Structure-activity relationships of flavonoids
for vascular relaxation in porcine coronary artery. Phytochemistry.
68:1179–1188. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin Y, Shi R, Wang X and Shen HM:
Luteolin, a flavonoid with potential for cancer prevention and
therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seelinger G, Merfort I, Wölfle U and
Schempp CM: Anti-carcinogenic effects of the flavonoid luteolin.
Molecules. 13:2628–2651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jeltsch A: Molecular enzymology of
mammalian DNA methyltransferases. Curr Top Microbiol Immunol.
301:203–225. 2006.PubMed/NCBI
|
|
26
|
Sankpal UT, Goodison S, Abdelrahim M and
Basha R: Targeting Sp1 transcription factors in prostate cancer
therapy. Med Chem. 7:518–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li L and Davie JR: The role of Sp1 and Sp3
in normal and cancer cell biology. Ann Anat. 192:275–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu J, Peng Y, Wu LC, Xie Z, Deng Y, Hughes
T, He S, Mo X, Chiu M, Wang QE, et al: Curcumin down-regulates DNA
methyltransferase 1 and plays an anti-leukemic role in acute
myeloid leukemia. PLoS One. 8:e559342013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Du L, Xie Z, Wu LC, Chiu M, Lin J, Chan
KK, Liu S and Liu Z: Reactivation of RASSF1A in breast cancer cells
by curcumin. Nutr Cancer. 64:1228–1235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chiu SJ, Chao JI, Lee YJ and Hsu TS:
Regulation of gamma-H2AX and securin contribute to apoptosis by
oxaliplatin via a p38 mitogen-activated protein kinase-dependent
pathway in human colorectal cancer cells. Toxicol Lett. 179:63–70.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Simbulan-Rosenthal CM, Rosenthal DS, Iyer
S, Boulares H and Smulson ME: IInvolvement of PARP and poly
(ADP-ribosyl)ation in the early stages of apoptosis and DNA
replication. Mol Cell Biochem. 193:137–148. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sellar GC, Watt KP, Rabiasz GJ, Stronach
EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B,
Scott D, et al: OPCML at 11q25 is epigenetically inactivated and
has tumor-suppressor function in epithelial ovarian cancer. Nat
Genet. 34:337–343. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J,
Zhang Q, Jin J, Liu D, Rhim JS, Rha SY, et al: OPCML is a broad
tumor suppressor for multiple carcinomas and lymphomas with
frequently epigenetic inactivation. PLoS One. 3:e29902008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu H, Zeng Z, Wang S, Li T, Mastriani E,
Li QH, Bao HX, Zhou YJ, Wang X, Liu Y, et al: Main components of
pomegranate, ellagic acid and luteolin, inhibit metastasis of
ovarian cancer by down-regulating MMP2 and MMP9. Cancer Biol Ther.
18:990–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Katalinić M, Rusak G, Domaćinović Barović
J, Sinko G, Jelić D, Antolović R and Kovarik Z: Structural aspects
of flavonoids as inhibitors of human butyrylcholinesterase. Eur J
Med Chem. 45:186–192. 2010. View Article : Google Scholar : PubMed/NCBI
|
